Molecular Monitoring in CML: Known Knowns, Known Unknowns, and Unknown Unknowns

This information was originally presented on September 19, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Differentiate the clinical evidence regarding the prognostic significance of early molecular response to TKI therapy and the importance of molecular monitoring with QPCR (IS)
Additional information
Supporters: 

Supported by educational grants from Foundation Medicine, Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Pharmacyclics, Inc. and Janssen Biotech, Inc.; and Takeda Oncology

Course summary
Available credit: 
  • 0.75 Participation
  • 0.63 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
11/06/2014
Course expires: 
11/06/2015
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 9th Annual Congress: Hematologic Malignancies™

Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Available Credit

  • 0.75 Participation
  • 0.63 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing